Major R&D Pipeline: 3ADCs
Major R&D Pipeline: 3ADCs
Daiichi-Sankyo
As of July 2021
Submitted
(JP/US) NSCLC, TNBC, HR+ BC
TROPION-PanTumor01
(JP/US/EU/Asia) NSCLC
(w/o actionable mutation,
pembrolizumab combo)
TROPION-Lung02
(JP/US/EU/Asia) NSCLC
(w/o actionable mutation,
durvalumab combo)
TROPION-Lung04
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) NSCLC
(JP/US)EGFR mutated NSCLC
(osimertinib combo)
(JP/US) BC
ENHERTU®
Dato-DXd
HER3-DXd
Phase 1
(US/EU/Asia) HER2+ BC 2L~/1L
DESTINY-Breast07
(US/EU/Asia) HER2 low BC
chemo naïve/ post chemo
DESTINY-Breast08
(US/EU/Asia) HER2+ GC combo,
2L~/1L
DESTINY-Gastric03
(EU/Asia)HER2+ NSCLC
(durvalumab combo) 1L
DESTINY-Lung03
(US/EU) BC, bladder
(nivolumab combo)
(US/EU) BC, NSCLC
(pembrolizumab combo)
Phase 2
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(US/EU) HER2+ GC 2L
DESTINY-Gastric02
Phase 3
(JP/US/EU/Asia) HER2+ BC 3L
DESTINY-Breast02
(JP/US/EU/Asia) HER2+ BC 2L
DESTINY-Breast03
(JP/US/EU)HER2+/mutated NSCLC 2L~(JP/US/EU/Asia) HER2 low BC
DESTINY-Lung01
(JP/US/EU/Asia)
HER2 mutated NSCLC 2L~
DESTINY-Lung02
(US/EU/Asia) NSCLC
(durvalumab combo) 2L~
HUDSON
(JP/US/EU) HER2+ CRC 3L
DESTINY-CRC01
(JP/US/EU/Asia) HER2+ CRC 3L
DESTINY-CRC02
(US/EU/Asia)
HER2 mutated tumor
DESTINY-PanTumor01
(US/EU/Asia)
HER2 expressing tumor
DESTINY-PanTumor02
(JP/US/EU/Asia) NSCLC
(w/ actionable mutation)
TROPION-Lung05
(JP/US/EU/Asia) EGFR mutated NSCLC
HERTHENA-Lung01
(JP/US/EU) CRC 3L
post chemo
DESTINY-Breast04
(JP/US/EU/Asia) HER2+ BC
post neoadjuvant
DESTINY-Breast05
(JP/US/EU/Asia) HER2 low BC
chemo naive
DESTINY-Breast06
(US) HER2+ BC 1L
DESTINY-Breast09
(JP/EU/Asia) HER2+ GC 2L
DESTINY-Gastric04
(JP/US/EU/Asia) NSCLC
(w/o actionable mutation)
TROPION-Lung01
BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer
: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
: Breakthrough Designation (US)
35View entire presentation